Almac Forms Academia-Industry Collaboration to Develop Green Chemicals
Almac announces its high level involvement in a synthetic biology project to develop novel routes to chemicals. Other partners in the academic–industry collaboration include Bangor University (Wales) and Hockley International (manufacturer and exporter of environmental health and industrial chemical products).
A grant of £1 million has been awarded to the research team by the Biotechnology & Biological Sciences Research Council and Technology Strategy Board. The funding is specifically targeted at bringing a novel chemical produced via an enzymatic route from under-utilised natural oil to the market.
Almac is currently performing the research and development work at its Northern Ireland-based laboratories. The company is partnering with scientific experts from both the University’s College of Natural Sciences and Hockley to progress the project over a three year period.
Professor Tom Moody, Head of Biocatalysis & Isotope Chemistry at Almac, commented: “Almac has cultivated considerable enzyme technology experience and expertise over the past decade and collaboration in this research is especially important for the development of green processes in this industry. Our expert team of scientists are excited to work on this project as we recognise the opportunity for researchers across industry and academia to work more closely together, sharing skills and knowledge to deliver truly excellent research that can make an impact not just on this project but also the UK. Indeed, we are delighted to be at the forefront of such partnerships.”
“It will form a close collaboration between Almac, Hockley and the University’s School of Biological Sciences, Biocomposites Centre,” explains Dr Viacheslav Tverezovskiy who is leading this research at Bangor University.
Frank Howard, MD and owner of Hockley International adds “We look forward to starting this major 3-year project in synthetic biology along with Almac and Bangor University which promises to be most exciting and scientifically challenging for us all.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance